Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5872 - Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Renal Cell Cancer

Presenters

Nazli Dizman

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

N. Dizman1, P. Bergerot1, C.D. Bergerot1, E.J. Philip2, M.M. Salgia1, J. Hsu1, J. Adashek1, S.K. Pal3

Author affiliations

  • 1 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 2 The Notre Dame Laboratory For Psycho-oncology Research, University of Notre Dame, 46556 - Notre Dame/US
  • 3 Medical Oncology Deparment, City of Hope, 91010 - Duarte/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5872

Background

A previous study identified an association between high body mass index (BMI) and better overall survival (OS) in mRCC patients treated with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) (Albiges et al JCO 2016). We assessed whether the effect of BMI on OS extended beyond VEGF-TKI to immunotherapy (IO) or VEGF/IO combination regimens.

Methods

A retrospective study was done among patients diagnosed with mRCC treated at a single institution from 2009 to 2017. Demographic and clinical variables were collected. BMI was characterized as high (≥25 kg/m2) versus low (<25 kg/m2). The Kaplan-Meier method was used to estimate the difference in OS, segregated by BMI and further by treatment type (e.g., VEGF-TKI, IO or VEGF/IO).

Results

Among 235 patients, median age was 65 years (33-90), 73% were male, and 65% were overweight or obese (BMI ≥ 25 kg/m2). The majority of patients had undergone nephrectomy (86%). The most systemic therapy was VEGF-TKI (58%), followed by IO (17%) and VEGF/IO (25%). In patients treated with VEGF-TKI with low BMI, median OS was 25.0 months (95% CI: 18.7-31.2) versus 36.0 months (95% CI: 25.2-46.7) in patients with high BMI (P = 0.01). A similar result was found for patients treated with VEGF/IO, where median OS was 18.0 months (95% CI:10.0-25.9) for patients with low BMI versus 24.0 months (95% CI: 14.8-33.2) in patients with high BMI (P = 0.01). However, patients treated with IO with low BMI, median OS was 55.0 months (95% CI: 33.7-76.7) versus 22.9 months (95% CI: 17.7-28.1) in patients with high BMI (P = 0.33).

Conclusions

High BMI was associated with improved OS in patients with mRCC treated with VEGF-TKI or VEGF/IO, but the inverse trend was observed among patients receiving IO. In addition to validating previous findings associating VEGF-TKI, BMI and clinical outcome, our data highlight the need to reassess this phenomenon in the context of IO-based regimens.

Clinical trial identification

Legal entity responsible for the study

City of Hope.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.